Biosimilars
- Biosimilar and Interchangeable Biologics: More Treatment Choices
- FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
- Biosimilar Product Information
Bladder Cancer
- Immunotherapy for Bladder Cancer – American Cancer Society
- Bladder Cancer – Nation Cancer Institute – For Patients
- Bladder Cancer – Nation Cancer Institute – For Providers
Breast Cancer
- National Cancer Institute: Breast (Patient Version)
- National Cancer Institute: Breast (Health Professional Version)
Colorectal Cancer (CRC)
- NCCN Guidelines for Colon Cancer
- NCCN Guidelines for Rectal Cancer
- Colorectal Cancer Alliance: What are NTRK fusions?
- National Cancer Institute: Colorectal Cancer [patient version]
- National Cancer Institute: Colorectal Cancer [health professional version]
- National Cancer Institute: Drugs Approved for Colon and Rectal Cancer
General Hematology/Oncology
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
- NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines for Patients
- CDC Recommended Screening Tests for Cancer
- American Cancer Society Guidelines for the Early Detection of Cancer
Hematologic Malignancies
- National Cancer Institute: Leukemia (Patient Version)
- National Cancer Institute: Leukemia (Health Professional Version)
- NCCN CLL Guidelines for Patients
- Leukemia & Lymphoma Society Patient Information Booklets
- Multiple Myeloma Research Foundation Patient Resources
Hematologic Malignancies and Disorders: Alpha Thalassemia
Hematologic Malignancies and Disorders: B-cell Lymphomas
- NCCN Guidelines for Patients: Mantle Cell Lymphoma
- NCCN Guidelines for Patients: Follicular Lymphoma
- NCCN Guidelines for Patients: DLBCL
- Leukemia & Lymphoma Society Patient Information Booklets
Hematologic Malignancies and Disorders: Chronic Lymphocytic Leukemia (CLL)
- CLL Guide: Information for Patients and Caregivers
- NCCN Guidelines: Chronic Lymphocytic Leukemia for Patients
Hematologic Malignancies and Disorders: Multiple Myeloma
- National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
- National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
- Treatment for Multiple Myeloma – for Health Professionals
- Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Hematologic Malignancies and Disorders: Myelodysplastic Syndromes (MDS)
- About Myelodysplastic Syndromes (MDS)
- Myelodysplastic Syndromes
- Treating MDS Toolkit
- What is MDS? iPad App
Hemophilia
- World Federation of Hemophilia Guidelines for the Management of Hemophilia
- National Hemophilia Foundation Recommendations for Genotyping for Persons with Hemophilia
- Impact of novel hemophilia therapies around the world
- Centers for Disease Control and Prevention: Hemophilia Homepage
- National Hemophilia Foundation: Hemophilia A
- World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition
Hepatocellular Carcinoma
- National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
- National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)
Kidney Cancer
Lung Cancer
- American Cancer Society Lung Cancer – Patient Information
- American Cancer Society Questions to Ask About Lung Cancer
- National Cancer Institute: Lung Cancer (Patient Version)
- National Cancer Institute: Lung Cancer (Health Professional Version)
Melanoma
- Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions
- Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
- Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
- Subcutaneous versus intravenous nivolumab
- Subcutaneous versus intravenous pembrolizumab
- First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
- Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial
- Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
- American Cancer Society: Immunotherapy for Melanoma Skin Cancer
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- NCI: Oncolytic Virus Enables the Immune System to Attack Tumors Subscribe
- NCCN Guidelines for Patients: Melanoma
- NCCN Clinical Practice Guidelines in Oncology – Cutaneous Melanoma
- Melanoma Treatment – for health professionals
- Melanoma Risk Assessment Tool
Ovarian Cancer
- SGO Gynecologic Cancer Resources For Patients And Their Families
- ACOG Ovarian Cancer FAQs
- Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer
- National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
- National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)
